Advertisement

Application of the LDL-Density-Pressure Theory: The Mitral Valve

  • Nalini M. Rajamannan
Chapter

Abstract

Myxomatous mitral valve regurgitation is the most common indication for surgical valve repair in the world [1]. For years this disease was thought to be a passive degenerative phenomenon. Understanding of the cellular mechanisms of this valve lesion will present improved understanding of this disease and targeted therapy either surgical or medical. Diagnosing mitral regurgitation (MR) and timing to surgical correction is one of the most challenging in the clinical cardiology. Chronic MR, due to increasing prevalence of myxomatous disease and the increasing mean age of population, is presenting as often as aortic stenosis: moderate or severe MR is found in 1.7 % of the general population and in up to 9.3 % of those over 75 years [1]. Echocardiography is the main tool for MR evaluation. In the modern times of mitral valve (MV) repair surgery, echocardiography has become even more important because the study has to cover not only the MR diagnosis, but also the evaluation of the valvular lesions and the mechanisms of disease to guide the election between the different therapeutic options. This combination of aspects related to the complexity of mitral regurgitation is the primary driving force to develop an all encompassing assessment of MR to allow the clinician and surgeon to achieve the important clinical outcomes. One of the key aspects for the elusiveness of this disease, from the clinical perspective, is the understanding of how the mitral valve develops myxomatous changes.

Keywords

Aortic Valve Mitral Valve Mitral Regurgitation Mitral Valve Repair Watchful Waiting 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Iung B, Vahanian A. Epidemiology of valvular heart disease in the adult. Nat Rev. 2011;8:162–72.Google Scholar
  2. 2.
    Rajamannan NM. Myxomatous mitral valve disease bench to bedside: LDL-density-pressure regulates Lrp5. Expert Rev Cardiovasc Ther. 2014;12(3):383–92.Google Scholar
  3. 3.
    Grande-Allen KJ, Griffin BP, Calabro A, Ratliff NB, Cosgrove 3rd DM, Vesely I. Myxomatous mitral valve chordae. Ii: selective elevation of glycosaminoglycan content. J Heart Valve Dis. 2001;10:325–32; discussion 332–3.PubMedGoogle Scholar
  4. 4.
    Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006;47:1707–12.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Bonow RO, Carabello BA, Chatterjee K, de Leon Jr AC, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM, Shah PM, Shanewise JS, Smith Jr SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B. Acc/aha 2006 guidelines for the management of patients with valvular heart disease: a report of the american college of cardiology/american heart association task force on practice guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the society of cardiovascular anesthesiologists endorsed by the society for cardiovascular angiography and interventions and the society of thoracic surgeons. J Am Coll Cardiol. 2006;48:e1–148.PubMedCrossRefGoogle Scholar
  6. 6.
    Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A. Guidelines on the management of valvular heart disease: the task force on the management of valvular heart disease of the european society of cardiology. Eur Heart J. 2007;28:230–68.PubMedGoogle Scholar
  7. 7.
    Nishimura RA, Otto C., et al. ACC/AHA 2014 Valvular Guidelines, JACC, In PressGoogle Scholar
  8. 8.
    Suri RM, Vanoverschelde JL, Grigioni F, Schaff HV, Tribouilloy C, Avierinos JF, Barbieri A, Pasquet A, Huebner M, Rusinaru D, Russo A, Michelena HI, Enriquez-Sarano M. Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets. JAMA. 2013;310:609–16.PubMedCrossRefGoogle Scholar
  9. 9.
    Bonow RO, Carabello BA, Kanu C, de Leon Jr AC, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM, Shah PM, Shanewise JS, Smith Jr SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Nishimura R, Page RL, Riegel B. Acc/aha 2006 guidelines for the management of patients with valvular heart disease: a report of the american college of cardiology/american heart association task force on practice guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease): developed in collaboration with the society of cardiovascular anesthesiologists: endorsed by the society for cardiovascular angiography and interventions and the society of thoracic surgeons. Circulation. 2006;114:e84–231.PubMedCrossRefGoogle Scholar
  10. 10.
    Ling LH, Enriquez-Sarano M, Seward JB, Orszulak TA, Schaff HV, Bailey KR, Tajik AJ, Frye RL. Early surgery in patients with mitral regurgitation due to flail leaflets: a long-term outcome study. Circulation. 1997;96:1819–25.PubMedCrossRefGoogle Scholar
  11. 11.
    Ling LH, Enriquez-Sarano M, Seward JB, Tajik AJ, Schaff HV, Bailey KR, Frye RL. Clinical outcome of mitral regurgitation due to flail leaflet. N Engl J Med. 1996;335:1417–23.PubMedCrossRefGoogle Scholar
  12. 12.
    Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M, Nkomo V, Scott C, Schaff HV, Tajik AJ. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med. 2005;352:875–83.PubMedCrossRefGoogle Scholar
  13. 13.
    Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, Schemper M, Maurer G, Baumgartner H. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation. 2006;113:2238–44.PubMedCrossRefGoogle Scholar
  14. 14.
    Ren JF, Panidis IP, Kotler MN, Mintz GS, Goel I, Ross J. Flail mitral valve syndrome: comparison with chronic mitral regurgitation of other etiologies. Am Heart J. 1985;109:435–42.PubMedCrossRefGoogle Scholar
  15. 15.
    Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, Schoen FJ. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation. 2001;104:2525–32.PubMedCrossRefGoogle Scholar
  16. 16.
    Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg T. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 2003;107:2181–4.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Lazaros G, Toutouzas K, Drakopoulou M, Boudoulas H, Stefanadis C, Rajamannan N. Aortic sclerosis and mitral annulus calcification: a window to vascular atherosclerosis? Expert Rev Cardiovasc Ther. 2013;11:863–77.PubMedCrossRefGoogle Scholar
  18. 18.
    Rajamannan NM, Spelsberg TC, Moura LM. Mitral valve disease in a patient with familial hypercholesterolemia. Rev Port Cardiol. 2010;29:841–2.PubMedCentralPubMedGoogle Scholar
  19. 19.
    Rajamannan NM, Spelsberg TC, Moura LM. Mitral valve disease in a patient with familial hypercholesterolemia. Rev Port Cardiol. 2010;29:841–2.PubMedCentralPubMedGoogle Scholar
  20. 20.
    Makkena B, Salti H, Subramaniam M, Thennapan S, Bonow RH, Caira F, Bonow RO, Spelsberg TC, Rajamannan NM. Atorvastatin decreases cellular proliferation and bone matrix expression in the hypercholesterolemic mitral valve. J Am Coll Cardiol. 2005;45:631–3.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Rajamannan NM. The role of lrp5/6 in cardiac valve disease: experimental hypercholesterolemia in the apoe-/-/lrp5-/- mice. J Cell Biochem. 2011;112:2987–91.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Rajamannan NM. The role of lrp5/6 in cardiac valve disease: Ldl-density-pressure theory. J Cell Biochem. 2011;112:2222–9.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Rajamannan NM. Bicuspid aortic valve disease: the role of oxidative stress in lrp5 bone formation. Cardiovasc Pathol. 2011;20:168–76.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the lrp5 receptor pathway. Circulation. 2005;112:I229–34.PubMedCentralPubMedGoogle Scholar
  25. 25.
    Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, McConnell JP, Singh RJ, Stone NJ, Bonow RO, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation. 2002;105:2660–5.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Icardo JM, Colvee E, Revuelta JM. Structural analysis of chordae tendineae in degenerative disease of the mitral valve. Int J Cardiol. 2013;167:1603–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Division of Biochemistry and Molecular BiologyMayo ClinicRochesterUSA

Personalised recommendations